Ortho Dermatologics

What Ortho Dermatologics does

Ortho Dermatologics is the U.S. prescription dermatology division of Bausch Health Companies Inc. (NYSE: BHC), headquartered at 400 Somerset Corporate Blvd., Bridgewater, NJ, with 251-500 employees. The company markets a portfolio of roughly 20 FDA-approved prescription products across acne vulgaris, plaque psoriasis, onychomycosis, atopic dermatitis, cutaneous T-cell lymphoma, and herpes simplex virus, including topical formulations (Altreno, Arazlo, Duobrii, Bryhali, Cabtreo, Onexton, Ziana, Clindagel), the topical antifungal Jublia, the injectable biologic Siliq (brodalumab), oral and topical Targretin, Elidel, Renova, Retin-A/Micro, Xerese, Zovirax, Noritate, Luzu, and Zyclara. Core technology centers on proprietary formulation platforms — water-based tretinoin lotion, combination corticosteroid/retinoid lotions, triple-combination acne gels, microsphere tretinoin delivery, and a French-origin water-based skin barrier emulsion (Biafine).

The business model is primarily B2B2C prescription drug sales: Ortho Dermatologics sells through field sales representatives to dermatologists, PAs, and NPs, with fulfillment at Walgreens and independent pharmacies via the Ortho Dermatologics Rx Access savings program. The company supplements this with direct-to-consumer e-commerce for its Biafine cosmeceutical through Amazon and the Ortho Dermatologics Direct platform, alongside partnership with the American Academy of Dermatology's Find a Derm locator. Revenue is not separately disclosed and is consolidated within Bausch Health's segment reporting. The company also invests in medical education (Derm Board Review Challenge, Dermatopathology Challenge, Podiatry Review Challenge, GenoDerm textbook), KOL engagement at AAD and Skin of Color Society symposia, and patient community programs including the ASPIRE HIGHER Scholarship (up to $10,000 to six students annually) and the AAD Diversity Program.

Name

Ortho Dermatologics

Legal name

Ortho Dermatologics

Website

https://ortho-dermatologics.com

Company type

Private

Operating status

Operating

Headcount range

251–500 employees

Short description

Ortho Dermatologics is the U.S. prescription dermatology division of Bausch Health, marketing roughly 20 FDA-approved prescription products for acne, psoriasis, onychomycosis, atopic dermatitis, CTCL, and herpes simplex to dermatologists and patients across U.S. pharmacies and DTC e-commerce channels.

Ownership category

akta.pro rank

Product category

Prescription Dermatology Pharmaceuticals

NAICS

Health and Personal Care Retailers (456), Soap and Cleaning Compound Manufacturing (32561), Cosmetics, Beauty Supplies, and Perfume Retailers (456120)

SIC

Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics (2840), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Perfumes, Cosmetics & Other Toilet Preparations (2844)

akta.pro primary industry

Dermatology Specialty Pharmaceuticals (HLAIACAL)

akta.pro secondary industries

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK), Dermocosmetics & Medical-Grade Skincare (CRABAAAF), Dermatology OTC & Skin Health (Acne Treatments, Eczema/Psoriasis OTC, Antifungals, Wart Removal) (CRADAMAF)

Keywords

• Prescription dermatology
• Topical medications
• Skincare products
• Dermatology treatments
• Cosmeceutical products

Headquarters

HQ city

Bridgewater

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Marketing or Sales, Supply Chain, Personnel, Technology or R&D, Operations

Revenue model

1. Prescription Dermatology Products: Ortho Dermatologics generates revenue through the sale of prescription dermatology medications and treatments. The company offers a wide range of FDA-approved products for conditions including acne, psoriasis, onychomycosis, atopic dermatitis, and other dermatoses. Revenue is generated through pharmaceutical product sales to healthcare providers and pharmacies.
2. Cosmeceutical Products: Sale of Biafine Skin Recovery Emulsion, a cosmeceutical skincare product, through online channels including Amazon and the Ortho Dermatologics Direct platform, as well as through dermatology practices.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Core offering

Ortho Dermatologics develops and markets FDA-approved prescription dermatology medications—including topical lotions, gels, creams, solutions, oral retinoids, and injectable biologics—for the treatment of acne vulgaris, plaque psoriasis, onychomycosis, atopic dermatitis, cutaneous T-cell lymphoma, cold sores, and other dermatoses. The company also sells the Biafine water-based skin barrier emulsion as a cosmeceutical skincare product through direct-to-consumer online channels in addition to dermatology practices.

Product overview

Ortho Dermatologics is one of the largest prescription dermatology companies, offering a comprehensive portfolio of FDA-approved treatments for various skin conditions including acne vulgaris, plaque psoriasis, atopic dermatitis, onychomycosis (toenail fungus), cutaneous T-cell lymphoma, and cold sores (herpes simplex virus). The product portfolio includes topical medications (lotions, gels, creams, solutions), injectable biologics, and oral medications. Key products include Altreno, Arazlo, Duobrii, Cabtreo, Jublia, and Siliq for core dermatology conditions, along with Bryhali, Clindagel, Elidel, Luzu, Noritate, Onexton, Renova, Retin-A, Retin-A Micro, Targretin, Xerese, Ziana, Zovirax, and Zyclara. The company also offers Biafine as an over-the-counter cosmetic skincare product. Ortho Dermatologics provides both prescription medications and consumer skincare products, with support resources including patient savings programs, provider educational tools, and board review challenges for healthcare professionals.

Differentiator

Problem solved

Functional benefit

Brands

• Altreno: Water-based lotion formulation of tretinoin (0.05%)
• Arazlo
• Bryhali
• Cabtreo
• Duobrii
• Jublia
• Siliq
• Biafine

Products and services

• Arazlo (tazarotene) Lotion, 0.045% Topical prescription lotion containing tazarotene for the treatment of acne vulgaris.
• Duobrii (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045% Topical prescription lotion combining a corticosteroid and a retinoid for the treatment of plaque psoriasis.
• Altreno (tretinoin) Lotion, 0.05% Water-based tretinoin lotion formulation for the treatment of acne vulgaris.
• Jublia (efinaconazole) Topical Solution, 10% Topical antifungal solution for the treatment of onychomycosis (toenail fungus).
• Cabtreo (clindamycin phosphate, adapalene, and benzoyl peroxide) Topical Gel, 1.2%/0.15%/3.1% Triple-combination topical gel for the treatment of acne vulgaris, combining an antibiotic, retinoid, and antibacterial agent.
• Siliq (brodalumab) Injection, 210 mg/1.5 mL Prescription injectable biologic for the treatment of plaque psoriasis, with a boxed warning about suicidal ideation and behavior.
• Bryhali (halobetasol propionate) Lotion, 0.01% Topical corticosteroid lotion for inflammatory skin conditions.
• Clindagel (clindamycin phosphate gel) Topical Gel, 1% Topical antibiotic gel for the treatment of acne vulgaris.
• Elidel (pimecrolimus) Cream, 1% Topical immunomodulator cream for the treatment of atopic dermatitis, with a boxed warning about long-term safety.
• Luzu (luliconazole) Cream Topical antifungal cream for the treatment of fungal skin infections.
• Noritate (metronidazole) Cream Topical antibiotic cream for the treatment of rosacea.
• Onexton (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/3.75% Combination topical gel for the treatment of acne vulgaris.
• Renova (tretinoin cream) Cream, 0.02% Topical retinoid cream for the treatment of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin.
• Retin-A (tretinoin) Cream, 0.05% Topical retinoid cream for the treatment of acne vulgaris.
• Retin-A Micro (tretinoin) Gel, 0.06%/0.08% Microsphere gel formulation of tretinoin for the treatment of acne vulgaris.
• Targretin (bexarotene) Capsules, 75 mg Oral retinoid capsules for the treatment of cutaneous T-cell lymphoma (CTCL), with a boxed warning about risk of birth defects.
• Targretin (bexarotene) Gel, 1% Topical gel formulation of bexarotene for the treatment of cutaneous T-cell lymphoma (CTCL).
• Xerese (acyclovir and hydrocortisone) Cream, 5%/1% Combination topical cream for the treatment of herpes simplex virus (cold sores).
• Ziana (clindamycin phosphate and tretinoin) Gel, 1.2%/0.025% Combination topical gel for the treatment of acne vulgaris.
• Zovirax (acyclovir) Cream, 5% Topical antiviral cream for the treatment of herpes simplex virus infections.
• Zyclara (imiquimod) Cream, 2.5%/3.75% Immune response modifier cream for the treatment of actinic keratoses and external genital warts.
• Biafine Topical Emulsion Water-based topical emulsion designed to support skin barrier function and hydration for dry, sensitive, or stressed skin.

Quantifiable outcome

• 6 students receive up to $10,000 each through ASPIRE HIGHER Scholarship annually
• +1 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered minor and core.

• Skin of Color Society (SOCS)minorGTM or Marketing Partner · 26 March 2026SOCS presented its 22nd Annual Scientific Symposium in conjunction with the American Academy of Dermatology Annual Meeting, with Ortho Dermatologics mentioned in the context of dermatology industry participation. The symposium convened nearly 500 attendees from 13 countries.
• Case Western Reserve University and University HospitalscoreStrategic or Co-development Partner · 13 January 2026Research partnership to conduct the first large-scale collaborative study examining how nail fungus (onychomycosis) affects athletic performance. The six-month study will recruit 100-200 collegiate and professional athletes across multiple sports, in partnership with UH Drusinsky Sports Medicine Institute. Initial results expected by June 2026. The research may also benefit military personnel and other groups facing similar risks.
• UH Drusinsky Sports Medicine InstitutecoreStrategic or Co-development PartnerPart of the University Hospitals system, this institute collaborates with Ortho Dermatologics on the nail fungus and athletic performance study, contributing sports medicine expertise.
• American Academy of DermatologyminorGTM or Marketing PartnerMajor dermatology conference partnership for annual meetings where Ortho Dermatologics participates and engages with healthcare professionals. SOCS held its symposium in conjunction with this event.
• American Academy of Dermatology Diversity ProgramminorOthersOrtho Dermatologics supports the AAD Diversity Program which is committed to fostering diversity, equity, and inclusion in dermatology, ensuring all members have opportunities to thrive and patients receive quality care regardless of background.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Galderma: Pure-play global dermatology company with prescription and aesthetic franchises across acne, psoriasis, rosacea, and onychomycosis. Directly comparable as a dermatology-focused specialty pharma peer competing for the same prescriber base and therapeutic indications.
• LEO Pharma: Specialty dermatology company with prescription treatments in psoriasis (Enstilar, Taclonex), atopic dermatitis (Adbry), and actinic keratosis. Comparable as a dermatology specialist targeting the same prescriber and therapeutic categories.
• Almirall: European dermatology-focused specialty pharma with prescription franchises in acne, psoriasis, and actinic keratosis. Direct comparable as a prescription dermatology specialist serving overlapping therapeutic areas.

Emerging players

• Dermavant Sciences: Late-stage dermatology company focused on topical therapies for plaque psoriasis and atopic dermatitis. Comparable as a focused dermatology developer competing in the same therapeutic categories as Ortho Dermatologics' psoriasis and atopic dermatitis brands.
• Arcutis Biotherapeutics: Dermatology-focused biopharma developing topical treatments for plaque psoriasis (Zoryve), atopic dermatitis, and seborrheic dermatitis. Comparable as a differentiated topical formulation player competing in overlapping indications.

Broad incumbents

• AbbVie: Global biopharma with leading dermatology/aesthetics franchises (Skyrizi in psoriasis, Rinvoq in atopic dermatitis, Allergan Aesthetics). Comparable as a broad incumbent competing against Ortho Dermatologics' psoriasis and acne portfolios with larger biologic offerings.
• Eli Lilly: Global biopharma with Taltz (ixekizumab) in plaque psoriasis and psoriatic arthritis and lebrikizumab in atopic dermatitis. Comparable as a broad incumbent in moderate-to-severe psoriasis where Ortho Dermatologics' Duobrii and Siliq compete.
• Novartis: Global biopharma with Cosentyx (secukinumab) as a leading IL-17 biologic in psoriasis. Comparable as a broad incumbent biologic competitor against Ortho Dermatologics' Siliq (also an IL-17 inhibitor) and Duobrii in the psoriasis category.
• Bristol-Myers Squibb: Global biopharma with Sotyktu (deucravacitinib) in plaque psoriasis. Comparable as a broad incumbent with an oral psoriasis therapy that competes for moderate-to-severe psoriasis patients that Ortho Dermatologics' injectable Siliq targets.
• Amgen: Global biopharma with Otezla (apremilast) in plaque psoriasis and psoriatic arthritis. Comparable as a broad incumbent offering a non-biologic oral option competing in moderate psoriasis where Ortho Dermatologics' topical Duobrii is positioned.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/orthodermatologics

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ortho Dermatologics